Effects of alpha lipoic acid as a supplement in obese children and adolescents

Amrousy, Doaa El; El-Afify, Dalia

doi:10.1016/j.cyto.2020.155084

Cited by 7 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additional 139 papers were excluded due to being pre-print papers ( n = 2), study protocols ( n = 6), reporting data from studies lacking of an appropriate placebo-controlled design for the supplementation ( n = 64), lacking of randomisation ( n = 5), testing the acute effect of ALA supplementation ( n = 7), testing ALA supplementation combined in nutraceutical compounds ( n = 27), testing intravenous treatment with ALA ( n = 11), testing topical treatment with ALA ( n = 4), lacking sufficient information about the nature of the adverse events ( n = 9), or reporting data overlapped with other publications ( n = 4) ( Supplementary file B ). Finally, 71 studies were eligible and included in the systematic review [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 ,…”

Section: Resultsmentioning

confidence: 99%

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

et al. 2020

View full text Add to dashboard Cite

Alpha-lipoic acid (ALA) is a natural short-chain fatty acid that has attracted great attention in recent years as an antioxidant molecule. However, some concerns have been recently raised regarding its safety profile. To address the issue, we aimed to assess ALA safety profile through a systematic review of the literature and a meta-analysis of the available randomized placebo-controlled clinical studies. The literature search included EMBASE, PubMed Medline, SCOPUS, Google Scholar, and ISI Web of Science by Clarivate databases up to 15th August 2020. Data were pooled from 71 clinical studies, comprising 155 treatment arms, which included 4749 subjects with 2558 subjects treated with ALA and 2294 assigned to placebo. A meta-analysis of extracted data suggested that supplementation with ALA was not associated with an increased risk of any treatment-emergent adverse event (all p > 0.05). ALA supplementation was safe, even in subsets of studies categorized according to smoking habit, cardiovascular disease, presence of diabetes, pregnancy status, neurological disorders, rheumatic affections, severe renal impairment, and status of children/adolescents at baseline.

show abstract

Section: Resultsmentioning

confidence: 99%

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For example, hypozincemia is often found in patients with obesity and diabetes, and taking zinc supplements reduces metabolic disorders and contributes to weight loss [20]. Taking α-LA also helps to reduce body weight in obese and overweight people and reduces the phenomena of oxidative stress, inflammation, and dysadipokinemia [21].…”

Section: клінічна та експериментальна медицина / Clinical and Experim...mentioning

confidence: 99%

The Effect of Lipoic Acid, Zinc Sulfate and Sodium Thiosulfate on H2 S Metabolism in Cardiovascular System of Rats in Experimental Obesity

Bobetska,

Zaichko

2023

VPBM

View full text Add to dashboard Cite

Вісник проблем біології і медицини -2023 -Вип. 4 (171) / Bulletin of problems in biology and medicine -2023 -Issue 4 (171) 134 КЛІНІЧНА ТА ЕКСПЕРИМЕНТАЛЬНА МЕДИЦИНА / CLINICAL AND EXPERIMENTAL MEDICINEMaterials and methods. The research material consisted of the results of examination and treatment of 140 patients diagnosed with varicose veins of the lower extremities at the Istanbul NS Clinic and the Yeni Ganja Medical Center during 2017-2020. Among the patients there were 98 men, 42 women, average age 57.1±0.62 years.The duration of diabetes mellitus was 13.8±0.33 years. At the same time, 98 (70%) patients had a history of diabetes mellitus of 10-14 years, 27 (19.29%) patients -15-19 years, 13 (9.29%) patients -20-24 years, and 2 (1.43%) patients had more than 25 years. The concentration of sugar in the blood was 183.9±4.9 mg/dl, and the amount of glycohemoglobin was 9.0±0.09%, varying from 7.5% to 11.9%.EVLA was performed for all patients after appropriate preoperative preparation. Depending on the energy density, the patients were divided into control and main groups. In 60 patients included in the control group, the speed limit of the extractor device was set at 1 mm/s, and the power was set at 8-10 Watts to supply 80-100 J/cm of energy to the vein. 80 patients of the main group were divided into 2 subgroups of 40 people each.Results and discussion. Varicose veins of the lower extremities are considered the most obvious clinical sign of chronic venous insufficiency. Varicose veins significantly decreased (p<0.0001) in the control group a week after EVLA. Varicose veins were not detected in 57.1% of patients on the right and 25 on the left. In 24 people on the left, the number and volume of varicose veins significantly decreased (p<0.0001) and decreased to the level to be assessed at 1 point.140 patients with diabetes mellitus underwent EVLA. In the control group (n=60), energy was applied in 80-100 J/cm; in the main A subgroup (n=40) 100-120 J/cm and in the main subgroup (n=40) 120-140 J/cm. The results on the VCSS scale were compared a week, 1 month, 6 months and 1 year after EVLA. The analysis proved that EVLA with an energy output of 120-140 J/cm is more effective in patients with diabetes mellitus.In our study, positive effect was confirmed by the best VCSS quality of life indicators and a significant reduction in the number of relapses after surgery in patients with diabetic varicose veins.

show abstract

“…A recent randomized, double-blind, placebo-controlled trial of obese youth ( n = 80) found that supplementation of ALA 300 milligrams twice daily for three months significantly improved BMI over the control group ( p < 0.05) although lipid profiles did not improve [ 89 ]. It is known that ALA exerts anti-inflammatory benefits [ 89 ].…”

Section: Managing Metabolic Syndrome In the Setting Of Sga Prescrimentioning

confidence: 99%

Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics

Rice

Ramtekkar

2020

Medical Sciences

View full text Add to dashboard Cite

Weight gain and metabolic syndrome are common side effects of second-generation antipsychotics and carry significant health consequences both in childhood and into adulthood. This review highlights evidence-based, non-pharmacologic interventions to assist in the management of these side effects. Such intervention categories include dietary, physical activity, sleep, stress management, and nutritional supplementation. Interventions with the highest quality evidence include increasing the consumption of fruits, vegetables, and whole grains, increasing physical activity, improving sleep, and fish oil supplementation. We suggest that clinicians work with patients on managing metabolic side effects in a patient-centered way, incorporating principles of motivational interviewing, to reduce the risk of metabolic syndrome.

show abstract

Effects of alpha lipoic acid as a supplement in obese children and adolescents

Cited by 7 publications

References 31 publications

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

Safety Evaluation of α-Lipoic Acid Supplementation: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Clinical Studies

The Effect of Lipoic Acid, Zinc Sulfate and Sodium Thiosulfate on H2 S Metabolism in Cardiovascular System of Rats in Experimental Obesity

Integrative Management of Metabolic Syndrome in Youth Prescribed Second-Generation Antipsychotics

Contact Info

Product

Resources

About